Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

Completed · Phase 4

Conditions studied: Migraine, Episodic Migraine, Phonophobia, Photophobia

In brief

The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.

Key facts

Study ID
NCT05207865
Run by
Pfizer
People needed
441
Starts
2022-03-15
Expected to finish
2024-07-02
Last updated by the study team
2025-09-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.